Prior Authorization Reform for Autoimmune and Blood Disorders Act
- Sponsor
- Rep. Johnson, Julie [D-TX-32]
- Committees
- Ways and Means Committee (primary)
- Last action
- Jun 8, 2026
Bottom line
The bill aims to improve access to essential medications and reduce administrative burdens for patients with chronic autoimmune and blood disorders by requiring coverage and streamlining prior authorization processes.
What it actually does
This bill mandates that group health plans and health insurance issuers provide coverage for drugs used to treat autoimmune diseases, hemophilia, and Von Willebrand disease. It also limits the frequency with which these plans can require prior authorization for such drugs to no more than once every 12 months, with specific exceptions for short-term use drugs, controlled substances, and drugs requiring a risk evaluation and mitigation strategy.
Proponents argue
Supporters argue that this legislation will significantly improve patient access to life-saving and life-altering medications for chronic conditions, reducing delays in care and administrative burdens for both patients and healthcare providers. They contend that frequent prior authorization requirements for long-term treatments are unnecessary and can lead to treatment interruptions, poorer health outcomes, and increased healthcare costs in the long run due to complications.
Opponents contend
Critics may contend that mandating coverage and restricting prior authorization frequency could lead to increased healthcare costs for health plans, employers, and ultimately, consumers through higher premiums. They might argue that prior authorization is a necessary tool for managing drug utilization, ensuring appropriate prescribing, and controlling overall healthcare expenditures, especially for expensive specialty drugs.
The bill is short and relatively straightforward, making it accessible for a reader to understand its core provisions within a short timeframe.
Section 2(a)(1), (b), (c)(1) amending ERISA Sec. 727(a)(1), PHS Act Sec. 2799A-12(a)(1), and IRC Sec. 9827(a)(1)
Mandatory Coverage for Autoimmune and Blood Disorder Drugs
This provision requires all group health plans and health insurance issuers to provide coverage for any drug classified as an 'autoimmune or blood disorder drug.' This coverage must be provided regardless of whether the drug is dispensed by a pharmacy or administered as part of another covered medical service. This ensures that patients with specified conditions have their necessary medications covered by their insurance.
Supporters argue
Supporters argue this provision is crucial for ensuring that individuals suffering from chronic and often debilitating autoimmune and blood disorders receive consistent access to the medications vital for managing their conditions and maintaining their quality of life.
Critics contend
Opponents might argue that mandating coverage for specific drug categories limits the flexibility of health plans to design cost-effective benefits packages and could lead to increased premiums for all enrollees, even those not affected by these conditions.
Tradeoffs
The provision balances the goal of ensuring comprehensive patient access to essential treatments against concerns about increasing healthcare costs and potentially reducing plan flexibility in benefit design.
Section 2(a)(1), (b), (c)(1) amending ERISA Sec. 727(a)(2), PHS Act Sec. 2799A-12(a)(2), and IRC Sec. 9827(a)(2)
Limitation on Prior Authorization Frequency
This provision stipulates that for autoimmune or blood disorder drugs, health plans and issuers cannot require prior authorization more than once during any 12-month period. This aims to reduce the administrative burden on patients and providers by streamlining the approval process for long-term medications, ensuring continuous access to treatment without repeated bureaucratic hurdles.
Section 2(a)(1), (b), (c)(1) amending ERISA Sec. 727(a)(2)(A)-(C), PHS Act Sec. 2799A-12(a)(2)(A)-(C), and IRC Sec. 9827(a)(2)(A)-(C)
Exceptions to Prior Authorization Frequency Limit
The bill outlines specific categories of drugs for which the 12-month prior authorization limit does not apply. These exceptions include drugs typically used for 12 months or less, controlled substances such as opioids, benzodiazepines, barbiturates, or carisoprodol, and drugs that require a Risk Evaluation and Mitigation Strategy (REMS) under federal law. This allows health plans to maintain more frequent prior authorization requirements for medications that pose higher risks, are prone to abuse, or are intended for short-term use.
The definition of 'autoimmune or blood disorder drug' is crucial, specifying that it means 'a drug or biological product that is indicated and prescribed for the treatment of an autoimmune disease, hemophilia, or Von Willebrand disease.'
Section 2(a)(1) amending ERISA Sec. 727(b), Section 2(b) amending PHS Act Sec. 2799A-12(b), and Section 2(c)(1) amending IRC Sec. 9827(b)
Why it matters:This is standard legislative practice to place definitions in a separate subsection. It is not intended to be evasive but is a technical detail that determines the full impact.
Case for: Defining the scope precisely ensures that the benefits of the bill are targeted to specific patient populations with chronic and often complex conditions, preventing unintended expansion or dilution of the policy's intent.
Case against: No specific case against the definition itself, but some might argue for the inclusion or exclusion of other specific diseases based on medical necessity or prevalence.
Estimated impact: This definition directly determines which patients and which drugs are affected by the mandatory coverage and prior authorization limits, thus shaping the entire fiscal and health impact of the bill.